This document discusses the Ebola virus vaccine market and pipeline. It notes that Ebola virus was discovered in 1976 and causes hemorrhagic fever. There is currently no licensed vaccine for Ebola virus infection. The document outlines that there are 26 Ebola vaccines in clinical trials, with 15 in preclinical development. It also discusses the opportunities for pharmaceutical companies to develop drugs and vaccines for Ebola virus infection given the significant unmet medical need and potential for high revenues from premium priced products if clinical success and regulatory approval are achieved.

1. Ebola Virus Vaccine Market & Pipeline Insight
For Sample Contact: neeraj@kuickresearch.com , +91-11-47067990 Page 1
Ebola virus infection, which was previously called Ebola hemorrhagic fever was discovered in
1976. The infection caused due to ebola virus originates from four different strains of ebola
virus. These viruses generally are known to affect non-human primates, and are transmitted
from wild animals to the humans and among the latter, it is known to spread through human-
to-human transmission. The natural hosts of ebola virus are Fruit bats, which belong to the
Pteropodidae family.
Ebola virus is mostly found among primates in the African region, (mainly in the remote
villages of Central and West Africa, near tropical rainforests) and in the Philippines. Other
than Africa, this infection has been observed in regions like Republic of Congo, Gabon, Sudan,
Ivory Coast and Uganda.
In terms of treatment, till date, there is not standard treatment method for Ebola
hemorrhagic fever. Only supportive therapy is available. Also, there is no licensed vaccine for
ebola virus infection which is of clinical use. The researchers have been trying to better
understand this virus and target its ecological reservoirs in order to get a deeper
understanding of the cause and nature of the outbreaks of this disease. There are currently
many experiments in the laboratories which are focusing on developing an appropriate
vaccine for the prevention of this disease, but no success has been met till now.
The pharma companies have a significant opportunity in the field of ebola virus infections in
terms of developing drugs, vaccines and introducing measures to control and prevent the
spread of the disease. After the success of the clinical candidates, and the market approval of
these drugs or vaccines, it is most likely that there could a significant demand for these
products from the physicians and patients. Additionally, due to the nature of the disease,
these products would be priced at a premium, which would eventually yield high revenues for
the companies which would earn a significant return on investment.
“Ebola Virus Vaccine Market & Pipeline Insight” Report Highlight:
• Ebola Virus Infection Market Overview
• Ebola Vaccine Clinical Trial Insight by Phase, Company & Country
• Ebola Vaccine in Clinical Trials: 26 Vaccine

2. Ebola Virus Vaccine Market & Pipeline Insight
For Sample Contact: neeraj@kuickresearch.com , +91-11-47067990 Page 2
• Majority Ebola Vaccine in Preclinical Phase: 15 Vaccines
• Ebola Vaccines by Mechanism of Action, Drug Class, Route of administration, Patent
Analysis & Licensing Status
For Report Sample Contact: neeraj@kuickresearch.com
Table of Contents
1. Ebola Virus Infection Market Overview
1.1 Symptoms & Diagnostics
1.2 Causes of Ebola Virus Infection
1.3 Incidence
1.4 Ongoing developments
1.5 Future Scenario
2. Ebola Vaccine Clinical Trial Overview
3. Ebola Vaccine Clinical Trial Insight by Phase, Company & Country
3.1 Research
3.2 Preclinical
3.3 Clinical
3.4 Phase-I
4. Suspended & Discontinued Ebola Vaccine Clinical Trial Insight by Phase, Company &
Country
4.1 No Development Reported
4.2 Discontinued
4.3 Suspended

3. Ebola Virus Vaccine Market & Pipeline Insight
For Sample Contact: neeraj@kuickresearch.com , +91-11-47067990 Page 3
5. Competitive Landscape
5.1 Bavarian Nordic
5.2 Crucell
5.3 Fab Entech
5.4 Inovio Pharmaceuticals
5.5 Microbiotix
5.6 Mitsubishi Tanabe Pharma
5.7 Profectus Biosciences
5.8 SIGA Technologies
5.9 Tekmira Pharmaceuticals
5.10 Vaxart
List of Figures
Figure 1-1: Ebola Incidence & Deaths, October’2014
Figure 2-1: Ebola Vaccine Clinical Trial by Phase (%), 2014
Figure 2-2: Ebola Vaccine Clinical Trial by Phase (Number), 2014
Figure 2-3: Suspended & Discontinued Ebola Vaccine in Clinical Trial by Phase (%), 2014
Figure 2-4: Suspended & Discontinued Ebola Vaccine in Clinical Trial by Phase (Number),
2014
Table 1-1: Ebola Incidence Since 1976
For Report Sample Contact: neeraj@kuickresearch.com